<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40397</article-id><article-id pub-id-type="doi">10.18821/1028-9984-2017-22-5-281-287</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">LEVELS OF GROWTH FACTORS AND THEIR RECEPTORS IN INTACT AND TUMOR TISSUES OF FEMALE MICE IN DYNAMICS OF THE MALIGNANT MELANOMA GROWTH</article-title><trans-title-group xml:lang="ru"><trans-title>СОДЕРЖАНИЕ ФАКТОРОВ РОСТА И ИХ РЕЦЕПТОРОВ В ИНТАКТНОЙ И ПАТОЛОГИЧЕСКИ ИЗМЕНЕННОЙ КОЖЕ САМОК МЫШЕЙ В ДИНАМИКЕ РОСТА ЗЛОКАЧЕСТВЕННОЙ МЕЛАНОМЫ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kit</surname><given-names>O. I</given-names></name><name xml:lang="ru"><surname>Кит</surname><given-names>О. И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Frantsiyants</surname><given-names>E. M</given-names></name><name xml:lang="ru"><surname>Франциянц</surname><given-names>Е. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bandovkina</surname><given-names>Valeriya A.</given-names></name><name xml:lang="ru"><surname>Бандовкина</surname><given-names>Валерия Ахтямовна</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, Senior Researcher of the Laboratory of Pathogenesis of Malignant Tumors, Rostov-on-Don, 344037, Russian Federation.</p></bio><bio xml:lang="ru"><p>канд. биол. наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей, 344037, г. Ростов-на-Дону, 14 линия, д. 63</p></bio><email>super.gormon@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kaplieva</surname><given-names>I. V</given-names></name><name xml:lang="ru"><surname>Каплиева</surname><given-names>И. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Trepitaki</surname><given-names>L. K</given-names></name><name xml:lang="ru"><surname>Трепитаки</surname><given-names>Л. К</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rozenko</surname><given-names>L. Ya</given-names></name><name xml:lang="ru"><surname>Розенко</surname><given-names>Л. Я</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Cheryarina</surname><given-names>N. D</given-names></name><name xml:lang="ru"><surname>Черярина</surname><given-names>Н. Д</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pogorelova</surname><given-names>Yu. A</given-names></name><name xml:lang="ru"><surname>Погорелова</surname><given-names>Ю. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shulga</surname><given-names>A. V</given-names></name><name xml:lang="ru"><surname>Шульга</surname><given-names>А. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Rostov Research Institute of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава РФ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2017</year></pub-date><volume>22</volume><issue>5</issue><issue-title xml:lang="en">VOL 22, NO5 (2017)</issue-title><issue-title xml:lang="ru">ТОМ 22, №5 (2017)</issue-title><fpage>281</fpage><lpage>287</lpage><history><date date-type="received" iso-8601-date="2020-07-22"><day>22</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Эко-Вектор"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/40397">https://rjonco.com/1028-9984/article/view/40397</self-uri><abstract xml:lang="en"><p>The formation and growth of the tumor are accompanied with the development of new vasculature providing the neoplasm with nutrients for its growth and metastasis. Main agents for these processes are VEGF family that can be activated by various ways, including insulin growth factor (IGF) effects, epidermal growth factors (EGF), transforming growth factors (TGF) and fibroblast growth factor (FGF). The study included female C57BL/6 mice (n = 40) with B16/F10 melanoma transplanted subcutaneously. Changes in levels of VEGF-A, VEGF-C, VEGF-D and their receptors R1, R2 in dependence on the activity of IGF-I, IGF-II, EGF and FGF21 were studied by ELISA in tumor, perifocal area and intact tissues in the dynamics of B16/F10 melanoma growth using standard test systems. VEGF-A and VEGF-C were first to be activated in intact tissue of female mice with transplanted tumors, even prior to the tumor formation, which created conditions for the growth and development of the malignant tumor stroma. Later development of B16 melanoma was accompanied by the enhanced expression of VEGF growth factors and receptors in tumor and surrounding tissues. Main factors triggering angiogenesis in all samples included IGF2 and IGF1 which levels in the dynamics of melanoma growth correlated with VEGF-A values in tumor, its perifocal zone and intact tissues, and with VEGF-C in non-malignant tissue. The study demonstrated the multifactor staged activation of neoangiogenesis not only in B16 melanoma tissue but in surrounding and intact tissues as well.</p></abstract><trans-abstract xml:lang="ru"><p>Образование и рост опухоли сопровождаются формированием новой сосудистой системы, обеспечивающей потребности неоплазмы в питательных веществах для роста и метастазирования. Основным агентом этих процессов является семейство факторов роста сосудистого эндотелия (VEGF), активация которого возможна разными путями, в том числе посредством действия инсулиновых факторов роста IGFs, эпидермального фактора роста EGF, трансформирующего фактора роста TGF и фактора роста фибробластов FGF. Исследования проводили у самок мышей линии C57BL/6 (n = 40) с перевитой подкожной меланомой B16/F10. В опухоли, перифокальной зоне и неповрежденной коже с помощью стандартных тест-систем методами ИФА изучали изменения уровня VEGF-A, VEGF-C, VEGF-D, а также их рецепторов - R1, R2, в зависимости от активности IGFI, IGFII, EGF, FGF21 в динамике роста меланомы B16/F10. В неповрежденной коже у самок мышей с перевитой опухолью, еще до выхода опухолевого узла, первыми активируются VEGF-A и VEGF-C, создавая условия для роста и развития стромы злокачественной опухоли. Затем развитие меланомы B16 сопровождается усилением выработки факторов роста и рецепторов семейства VEGF в ткани опухоли и окружающих её тканях. При этом у самок мышей основными во всех исследуемых образцах факторами «запуска» ангиогенеза явились факторы семейства инсулиноподобных - IGFII, и IGFI, показатели которых коррелировали в динамике роста меланомы со значениями VEGF-A в ткани опухоли, её перифокальной зоны и непораженной коже, а также с VEGF-C в непораженной злокачественным процессом коже. В результате исследований установлена многофакторная ступенчатая активация неоангиогенеза не только в ткани меланомы B16, но и в окружающем её регионе и в неповреждённой коже.</p></trans-abstract><kwd-group xml:lang="en"><kwd>growth factors</kwd><kwd>growth factor receptors</kwd><kwd>neoangiogenesis</kwd><kwd>lymphangiogenesis</kwd><kwd>B16/F10 melanoma</kwd><kwd>perifocal zone</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>факторы роста</kwd><kwd>рецепторы факторов роста</kwd><kwd>неоангиогенез</kwd><kwd>лимфангиогенез</kwd><kwd>меланома B16/F10</kwd><kwd>перифокальная зона</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Чехонин В.П., Шеин С.А., Корчагина А.А., Гурина О.И. Роль VEGF в развитии неопластического ангиогенеза. Вестник РАМН. 2012; (2): 23-33.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ferrara N., Gerber H.P., Le Couter J. The biology of VEGF and its receptors. Nature Med. 2003; 9 (6): 669-76.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Wang X., Chen X., Fang J., Yang C. Over expression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int. J. Clin. Exp. Pathol. 2013; 6(4): 586-97.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Capoluongo E., Ameglio F., Zuppi S. Insulin-like growth factor-I and complications of prematurity: Focus on bronchopulmonary dysplasia. Clin. Chem. Lab. Med. 2008; 46: 1061-6.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Roddam A.W., Allen N.E., Appleby P., Key T.J., Ferrucci, Carter H.B. et al. (2008), Insulin like growth factors and their binding proteins, and the risk of prostate cancer: Analysis of individual patient data from 12 prospective studies. Ann. Intern. Med. 2008; 149: 461-71.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Duffy M.J., O,Donovan N., Grown J. Use of molecular markers for predicting therapy response in cancer patients. J. Cancer Treatment Reviews. 2011; 37(2):151-9. DOI: 10.1016/j.ctrv.2010.07.004.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bracher A., Cardona A.S., Tauber S., Fink A.M., Steiner A., Pehamberger H. et al. Epidermal growth factor promotes melanoma lymph node metastasis by acting on tumor lymphangiogenesis. J. Invest. Dermatol. 2013; 133(1): 230-8. DOI: 10.1038 /jid.2012.272. Epub 2012 September 6th.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Akslen L.A., Puntervoll H., Bachmann I.M., Straume O., Vuhahula E., Kumar R., Molven A. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanoma from black Africans and other subgroups of cutaneous melanoma. Melanoma Res. 2008; 18(1): 29-35. doi: 10.1097/CMR.0b013e3282f32517</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGF-beta activation. J. Cell. Sci. 2003; 116: 217-24.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Javelaud D., Alexaki V.I, Mauviel A. Transforming growth factor-BETA in cutaneous melanoma. Pigment Cell Melanoma Res. 2008; 21(2): 123-32. DOI: 10.1111 / j.1755-148X.2008.00450.x</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Santos Bernardes S., de Souza-Neto F.P., Melo G.P., Guarnier F.A., Marinello P.C., Cecchini R., Cecchini A.L. Correlation of TGF-β1 and oxidative stress in the blood of patients with melanoma: a clue to understanding melanoma progression? Tumour Biol. 2016; 37(8): 10753-61.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Cantelli G., José L., Rodriguez-Hernandez I., Karagiannis P., Maiques O., Matias-Guiu X. et al. TGF-β-induced transcription Braves Melanoma amoeboid migration and proliferation. Curr. Biol. 2015; 25(22): 2899-914. DOI: 10.1016 / j.cub.2015.09.054. PMCID: PMC4651903</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Choi M., Moschetta A., Bookout A.L., Peng L., Umetani M., Holmstrom S.R. et al. Definition of a hormonal basis for filling the gallbladder. Nat. Med. 2006; 12: 1253-5.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Chow M.D.L., Gao J., Qing Y., Zhidan W., Gromada J. Fibroblast growth factor 21 regulates energy metabolism through activation of AMPK-SIRT1-PGC-1alpha pathway. Proc. Nat. Acad. Sci. USA. 2010; 107(28): 12553-8. DOI: 10.1073 / pnas.1006962107 PMCID: PMC2906565</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Hori M., Shimizu Y., Fukumoto S. Minireview: fibroblast growth factor-23 in phosphate homeostasis and bone metabolism. Endocrinology. 2011; 152: 4-10.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Feng S., Dakhova O., Creighton C.J., Ittmann M. Endocrine FGF19 fibroblast growth factor promotes the development of prostate cancer. Cancer Res. 2013; 73(8): 2551-62. DOI: 10,1158 / 0008-5472.CAN-12-4108</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Франциянц Е.М., Бандовкина В.А., Каплиева И.В., Трепитаки Л.К., Погорелова Ю.А., Черярина Н.Д. Факторы роста эндотелия сосудов и рецепторов в динамике развития перевиваемой меланомы B16/F10. Российский онкологический журнал. 2015; 20(2): 32-7.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Treshchalina E.M., Zhukova O.S., Gerasimova G.K., Andronova N.V., Garin A.M. The guidelines for conducting pre-clinical testing of medicines. M.: Grif i K; Ch.1. 2012: 642-57.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Vartanian A. Signaling pathways in tumor vasculogenic mimicry. Biochemistry. 2012; 77(9): 1044-55.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zeng Y., Opeskin K., Goad J., Williams T.D. Tumor-Induced Activation of Lymphatic Endothelial Cells via Vascular Endothelial Growth Factor Receptor-2 Is Critical for Prostate Cancer Lymphatic Metastasis. Cancer Res. 2006; 66(1): 9566-75.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>He Y., Rajantie I., Ilmonen M., Makinen T., Karkkainen M.J., Haiko P. et al. Preexisting Lymphatic Endothelium but not Endothelial Progenitor Cells Are Essential for Tumor Lymphangiogenesis and Lymphatic Metastasis. Cancer Research. 2004; (64): 3737-40.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Lee S., Safdie F.M., Raffaghello L., Wei M., Madia F., Parrella E., Hwang J., Cohen P. Reduced levels of IGF-I mediates the differential protection of normal and cancer cells in response to the post and improve the chemotherapeutic index. Cancer Res. 2010; 70: 1564-72.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Satyamoorthy K., Li G., Vaidya B., Kalabis J.M. Herlin insulin-like growth factor-I-induced migration of melanoma cells is mediated by IL-8 induction. The growth of the cells are different. 2002; 13: 87-93.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Pollack M. Insulin and insulin-like growth factor-like signaling in neoplasia. Nature Rev. Cancer. 2008; 8: 915-28.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Бабышкина Н.Н., Малиновская Е.А., Стахеева М.Н., Волкоморов В.В., Уфандеев А.А., Слонимская Е.М. Роль трансформирующего ростового фактора TGF-β1 в патогенезе рака молочной железы. Сибирский онкологический журнал. 2010; 6: 42: 63-70.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Humbert L., Ghozlan M., Canaff L., Tian J., Lebrun J.J. Leukemia inhibitory factor (LIF) and p21 mediates tumor TGF-beta-suppressing effects in the skin of human melanoma. BMC Cancer. 2015; 15: 200. DOI: 10,1186/ s12885-015-1177-1</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Tan M.R., Wang Y.X., Guo S., Han S.Y., Li H.H., Jin S.F. Prognostic value of plasma and at levels of transforming growth factor beta 1, -2 and -3 in cutaneous melanoma. Mol. Med. Rep. 2015; 11(6): 4508-12. DOI: 10,3892 / mmr.2015.3250. Epub 2015 Jan. 26</mixed-citation></ref></ref-list></back></article>
